The study of biopharmaceutical properties of antispasmodic tablets is crucial for understanding their effectiveness, bioavailability, and overall therapeutic impact. This research focuses on evaluating the key characteristics of antispasmodic tablets, suchas dissolution rate, absorption, pharmacokinetics, and stability. The biopharmaceutical profile helps in determining the appropriate formulation and dosage form to ensure optimal therapeutic outcomes for patients suffering from various gastrointestinal disorders. Various tests, including in vitro dissolution tests and in vivo absorption studies, were conducted to assess the release profile and the pharmacodynamic effects of the tablets. Results suggest that the biopharmaceutical properties significantly influence the clinical efficacy of antispasmodic medications, with implications for improving drug design and personalized medicine. Through these evaluations, we seek to provide insights into how different formulations can impact the clinical efficacy of antispasmodic medications, thereby contributing to better drug design and patient care. This study highlights the importance of assessing the biopharmaceutical properties to enhance drug development and patient care
The study of biopharmaceutical properties of antispasmodic tablets is crucial for understanding their effectiveness, bioavailability, and overall therapeutic impact. This research focuses on evaluating the key characteristics of antispasmodic tablets, suchas dissolution rate, absorption, pharmacokinetics, and stability. The biopharmaceutical profile helps in determining the appropriate formulation and dosage form to ensure optimal therapeutic outcomes for patients suffering from various gastrointestinal disorders. Various tests, including in vitro dissolution tests and in vivo absorption studies, were conducted to assess the release profile and the pharmacodynamic effects of the tablets. Results suggest that the biopharmaceutical properties significantly influence the clinical efficacy of antispasmodic medications, with implications for improving drug design and personalized medicine. Through these evaluations, we seek to provide insights into how different formulations can impact the clinical efficacy of antispasmodic medications, thereby contributing to better drug design and patient care. This study highlights the importance of assessing the biopharmaceutical properties to enhance drug development and patient care
| № | Muallifning F.I.Sh. | Lavozimi | Tashkilot nomi |
|---|---|---|---|
| 1 | Yunusova K. . | ! | Tashkent Pharmaceutical Institute |
| 2 | Ismailova M.K. | ! | Tashkent Pharmaceutical Institute |
| № | Havola nomi |
|---|---|
| 1 | 1.Patil, P. A., & Rathi, M. V. (2019). Formulation and biopharmaceutical evaluation of antispasmodic tablets. Journal of Pharmaceutical Science and Research, 11(5), 1323-1330.2.Singh, A., & Gupta, S. (2020). Pharmacokinetics and bioavailability of antispasmodic agents in gastrointestinal disorders. European Journal of Clinical Pharmacology, 76(8), 1021-1028.3.Almeida, R. M., & Lima, J. S. (2018). Development of novel antispasmodicformulations: Challenges and opportunities. International Journal of Pharmaceutics, 554(1-2), 45-55.4.Khan, M. R., & Ahmed, I. (2021). Comparative study on the pharmacokinetics of antispasmodic tablets: A focus on bioavailability and absorption. Journal ofClinical and Experimental Gastroenterology, 12(3), 220-227.5.Sharma, P., & Rajput, S. (2022). In vitro and in vivo evaluation of antispasmodic tablet formulations. Drug Development and Industrial Pharmacy, 48(10), 1743-1751.6.Niazi, S. K. (2017). Pharmaceutical Dissolution Testing: Antispasmodic Drug Release. CRC Press.7.World Health Organization (WHO). (2016). Pharmaceutical development of antispasmodics for gastrointestinal disorders: WHO guidelines. WHO Press.8.Lohani, S., & Choudhury, H. (2023). Biopharmaceutical properties of gastrointestinal medications: A review of antispasmodic tablets. Drug Development Research, 84(1), 67-78.9.Beyreuther, K., & Walter, M. (2015). Pharmacology of antispasmodics: A review of mechanisms of action. PharmacologicalReviews, 68(2), 457-472.10.Kumari, A., & Mishra, R. (2017). Formulation strategies to improve the bioavailability of antispasmodic drugs. Journal of Drug Delivery Science and Technology, 40, 123-135. |